Back to Search Start Over

[Radiotherapy for soft tissue sarcomas: Technical evolution and impact on clinical benefit]

Authors :
C, Llacer-Moscardo
C, Bourgier
A, Morel
P, Fenoglietto
S, Carrère
N, Firmin
D, Azria
Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM)
CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
Service de radiothérapie
Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
Département de chirurgie
CRLCC Val d'Aurelle - Paul Lamarque
Département d'oncologie Médicale
Source :
Cancer Radiothérapie, Cancer Radiothérapie, Elsevier Masson, 2016, 20 (6-7), pp.666-676. ⟨10.1016/j.canrad.2016.07.074⟩
Publication Year :
2016
Publisher :
HAL CCSD, 2016.

Abstract

International audience; The standard treatment for extremity soft tissue sarcomas is based on the association of surgery and radiotherapy. This strategy allows local control improvement with the risk of increased toxicity. There is therefore a growing interest to identify those patients who will benefit from radiotherapy and those who will have the same local control with surgery alone. Furthermore, the development of toxicity has been correlated with the extension of the irradiated volume and the volume receiving high doses. Technological development as intensity modulated radiotherapy and image-guided radiotherapy allows limited irradiated volume improving the protection of the organs at risk leading to clinical benefit improvement. Moreover, efforts are being done to improve local control for the patients at high risk of local relapse. In this paper, we discuss all these mentioned aspects.

Details

Language :
French
ISSN :
12783218
Database :
OpenAIRE
Journal :
Cancer Radiothérapie, Cancer Radiothérapie, Elsevier Masson, 2016, 20 (6-7), pp.666-676. ⟨10.1016/j.canrad.2016.07.074⟩
Accession number :
edsair.pmid.dedup....7a94e4370da343fb77fdb080132e6e97
Full Text :
https://doi.org/10.1016/j.canrad.2016.07.074⟩